Skip to main content
UL

Ultragenyx Pharmaceutical

Novato, United States
Last funding
$400.0M
Post-IPO DebtNov 2025

Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

Backed byTakedaHealthCapTPG GrowthF-PrimeAdage Capital Management

About Ultragenyx Pharmaceutical

How much funding has Ultragenyx Pharmaceutical raised?

Ultragenyx Pharmaceutical has raised $400.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in November 2025.

Who are Ultragenyx Pharmaceutical's investors?

Ultragenyx Pharmaceutical's investors include Takeda, HealthCap, TPG Growth, F-Prime, Adage Capital Management.

Where is Ultragenyx Pharmaceutical headquartered?

Ultragenyx Pharmaceutical is headquartered in Novato, United States.

What does Ultragenyx Pharmaceutical do?

Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

What stage is Ultragenyx Pharmaceutical at?

Ultragenyx Pharmaceutical is at the Post-IPO Debt stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Ultragenyx Pharmaceutical — Funding & Investors." VCBacked, November 4, 2025, https://www.vcbacked.co/company/ultragenyx-pharmaceutical. Accessed November 14, 2026.
APA
VCBacked. (2025). Ultragenyx Pharmaceutical — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/ultragenyx-pharmaceutical
Wikipedia (cite web)
{{cite web |title=Ultragenyx Pharmaceutical — Funding & Investors |url=https://www.vcbacked.co/company/ultragenyx-pharmaceutical |website=VCBacked |access-date=November 14, 2026}}

Profile data sourced and verified per the VCbacked methodology · Last funding round dated

Work at Ultragenyx Pharmaceutical? Request a listing update

Founder contacts
m***@ultragenyx.com
linkedin.com/in/●●●●●●
Emails, phones & LinkedIn · 41,000+ verified contacts
Get instant access →